BACKGROUND AND OBJECTIVES: The complexity of CKD management in children is increased by the number of comorbid conditions. This study assessed the prevalence of comorbidities in pediatric CKD and the frequency with which multiple comorbidities present together by assessing prevalent medication use by CKD stage and diagnosis and their association with clinical or sociodemographic factors. The association between number and frequency of dosing of medications prescribed and self-report of nonadherence was also assessed. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: In this cross-sectional analysis of the Chronic Kidney Disease in Children study, medication use at study entry grouped by indication was examined by CKD stage, diagnosis, age, race, ethnicity, income, and CKD duration. Multivariate adjusted predictors of medication use and clustering were examined. Nonadherence was assessed by self-report of missed medications in the past 7 days. RESULTS: The 558 eligible participants had a median age of 11 years and median GFR of 44 ml/min per 1.73 m(2); 62% of participants were male and 78% had nonglomerular kidney disease. The number of medications for treatment of CKD comorbidities increased with advanced CKD stage (2.5-fold for stages IV versus II; P<0.001) and glomerular disease (1.4-fold versus nonglomerular; P<0.001). Three distinct medication clusters were identified that corresponded to treatment of glomerular disease, advanced renal tubular dysfunction, and proteinuric complications, respectively. Nonadherence was associated with increased medication dosing frequency (administration >2 times/d; P<0.001) but not the number of medications. CONCLUSIONS: Medical therapy for children with CKD is complex and is affected by glomerular diagnosis, CKD stage, and medication frequency. The need for CKD-related medication treatment cannot be easily predicted by CKD staging alone. Poorer adherence was associated with increased medication frequency, but not with the number of medical problems needing treatment. Consolidating medical treatment and reducing medication frequency may improve adherence rates in children with CKD.
BACKGROUND AND OBJECTIVES: The complexity of CKD management in children is increased by the number of comorbid conditions. This study assessed the prevalence of comorbidities in pediatric CKD and the frequency with which multiple comorbidities present together by assessing prevalent medication use by CKD stage and diagnosis and their association with clinical or sociodemographic factors. The association between number and frequency of dosing of medications prescribed and self-report of nonadherence was also assessed. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: In this cross-sectional analysis of the Chronic Kidney Disease in Children study, medication use at study entry grouped by indication was examined by CKD stage, diagnosis, age, race, ethnicity, income, and CKD duration. Multivariate adjusted predictors of medication use and clustering were examined. Nonadherence was assessed by self-report of missed medications in the past 7 days. RESULTS: The 558 eligible participants had a median age of 11 years and median GFR of 44 ml/min per 1.73 m(2); 62% of participants were male and 78% had nonglomerular kidney disease. The number of medications for treatment of CKD comorbidities increased with advanced CKD stage (2.5-fold for stages IV versus II; P<0.001) and glomerular disease (1.4-fold versus nonglomerular; P<0.001). Three distinct medication clusters were identified that corresponded to treatment of glomerular disease, advanced renal tubular dysfunction, and proteinuric complications, respectively. Nonadherence was associated with increased medication dosing frequency (administration >2 times/d; P<0.001) but not the number of medications. CONCLUSIONS: Medical therapy for children with CKD is complex and is affected by glomerular diagnosis, CKD stage, and medication frequency. The need for CKD-related medication treatment cannot be easily predicted by CKD staging alone. Poorer adherence was associated with increased medication frequency, but not with the number of medical problems needing treatment. Consolidating medical treatment and reducing medication frequency may improve adherence rates in children with CKD.
Authors: N Gianotti; L Galli; B Bocchiola; T Cahua; P Panzini; D Zandonà; S Salpietro; M Maillard; A Danise; A Pazzi; A Lazzarin; A Castagna Journal: HIV Med Date: 2012-09-20 Impact factor: 3.180
Authors: Jemma L O'Connor; Edward M Gardner; Sharon B Mannheimer; Alan R Lifson; Stefan Esser; Edward E Telzak; Andrew N Phillips Journal: J Infect Dis Date: 2012-11-29 Impact factor: 5.226
Authors: Cyd K Eaton; Michelle N Eakin; Shayna Coburn; Cozumel S Pruette; Tammy M Brady; Barbara A Fivush; Susan Mendley; Shamir Tuchman; Kristin A Riekert Journal: J Pediatr Psychol Date: 2019-01-01
Authors: Edwin Patino; Stephen B Doty; Divya Bhatia; Kelly Meza; Yuan-Shan Zhu; Stefano Rivella; Mary E Choi; Oleh Akchurin Journal: Kidney Int Date: 2020-06-20 Impact factor: 10.612
Authors: Cynthia Wong; Arlene Gerson; Stephen R Hooper; Matthew Matheson; Marc Lande; Juan Kupferman; Susan Furth; Bradley Warady; Joseph Flynn Journal: Pediatr Nephrol Date: 2016-02-08 Impact factor: 3.714
Authors: Elaine Ku; Richard N Fine; Chi-Yuan Hsu; Charles McCulloch; David V Glidden; Barbara Grimes; Kirsten L Johansen Journal: Clin J Am Soc Nephrol Date: 2016-03-01 Impact factor: 8.237
Authors: Nancy M Rodig; Kelly C McDermott; Michael F Schneider; Hilary M Hotchkiss; Ora Yadin; Mouin G Seikaly; Susan L Furth; Bradley A Warady Journal: Pediatr Nephrol Date: 2014-04-12 Impact factor: 3.714
Authors: Oleh M Akchurin; Michael F Schneider; Lucy Mulqueen; Ellen R Brooks; Craig B Langman; Larry A Greenbaum; Susan L Furth; Marva Moxey-Mims; Bradley A Warady; Frederick J Kaskel; Amy L Skversky Journal: Clin J Am Soc Nephrol Date: 2014-06-26 Impact factor: 8.237
Authors: Meredith A Atkinson; Derek K Ng; Bradley A Warady; Susan L Furth; Joseph T Flynn Journal: Pediatr Nephrol Date: 2020-02-03 Impact factor: 3.714